# **Capsule Summary**

# Real world Effectiveness of the Pfizer COVID-19 Vaccine

- A vaccine effectiveness is the measure of how well a vaccine performs in the real world. It is measured by how well the vaccines work to protect communities as a whole (1).
- Vaccine effectiveness is analysed using observational studies where unlike a clinical trial, the participants are not randomly assigned
  to treatment and a placebo group. A case-control study is commonly used to analyse vaccine effectiveness.
- In a case control study, the vaccination status of the individuals who develop the disease (cases) is compared with the individuals who do not develop the disease (controls) (2).
- A study recently published in the lancet analysed the effectiveness of the BNT162b2 (Pfizer-BioNTech) vaccine in individuals 12 years or older. We have summarized the study findings below. You can access the entire study here

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02183-8/fulltext

## **Study Population:**

The electronic health records of individuals (≥12 years) who were members of the health-care organization Kaiser Permanente Southern California (CA, USA) were assessed. This study included 3436957 females and 1 637394 males.

## **Study Endpoints:**

BNT162b2 vaccine effectiveness against SARS-CoV-2 infections and COVID-19-related hospital admissions was assessed for up to 6 months. The study outcomes included SARS-CoV-2 PCR-positive tests and COVID-19-related hospital admissions. Effectiveness calculations were based on hazard ratios from adjusted Cox models.

#### Findings:Study

Effectiveness against SARS-COV-2 infection in fully vaccinated individuals	73%
Aston MartinEffectiveness against COVID-19 related hospital admissions	90%
Effectiveness against delta variants	93% during the 1st month after full vaccination but declined to 53% after 4 months
Efectiveness against other variants	For first month after full vaccination it was 97% but waned to 67% at 4–5 months
Vaccine effectiveness against hospital admissions for infections with the delta variant for all ages	93% up to 6 months

#### References:

https://www.who.int/news-room/feature-stories/detail/vaccine-efficacy-effectiveness-and-protection https://www.gavi.org/vaccineswork/what-difference-between-efficacy-and-effectiveness

Copyright Reserved @2021 independent Publication from Biourbexer Solutions. Please contact us at Contact@biourbexer.com for any queries.

#### Disclaimer

The information presented in this article is for informational and educational purposes only and does not substitute professional medical advice and consultation with healthcare professionals.